Hansen Gwenn
Nurix Therapeutics, Inc. · Chief Scientific Officer
Hansen Gwenn is listed in filings as Chief Scientific Officer at Nurix Therapeutics, Inc.. This profile follows SEC Form 4 activity through Jun 25, 2026, including sale activity. Recent filings connect the profile to Nurix Therapeutics, Inc. (NRIX). The current snapshot covers public activity from Jul 30, 2024 to Jun 25, 2026. Reported amounts are shown as $107.9K to $83.5K. The page organizes purchases, sales, issuer links, reported share activity, and filing evidence for review as public disclosure data.
History Trades
| Company | Value | Action | Price | Last Price |
|---|---|---|---|---|
| $70k3.4k shares | SellJul 30, 2024 | $20.67 | $23.07 | |
| $84k3.4k shares | SellOct 30, 2024 | $24.31 | $23.07 | |
| $6.8k333 shares | SellJan 30, 2025 | $20.33 | $23.07 | |
| $66k3.4k shares | SellJan 30, 2025 | $19.81 | $23.07 | |
| $39k3.4k shares | SellApr 30, 2025 | $11.50 | $23.07 | |
| $52k4.3k shares | SellJul 30, 2025 | $12.01 | $23.07 | |
| $52k4.1k shares | SellOct 30, 2025 | $12.80 | $23.07 | |
| $1.7k98 shares | SellJan 30, 2026 | $17.37 | $23.07 | |
| $80k4.8k shares | SellJan 30, 2026 | $16.58 | $23.07 | |
| $53k3.2k shares | SellApr 30, 2026 | $16.65 | $23.07 |